BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

FY25 appropriations for the National Cancer Institute, specifically funding for programs related to the Childhood Cancer STAR Reauthorization Act and the Childhood Cancer Data Initiative (CCDI); FY25 appropriations for the Department of Defense Congressionally-directed Medical Research Programs; FY25 appropriations for the Food and Drug Administration

HR 1692 / S 8, the Health Care Affordability Act; HR 2630 / S 652, the Safe Step Act; HR 3433 / S 2897, the Give Kids a Chance Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; HR 6003 / S 3103, the Medical Debt Relief Act; HR 6301 / S. 2039, The Cancer Drug Parity Act; HR 7383 / S 1214, the RARE Act; HR 824, the Telehealth Benefit Expansion for Workers Act; HR 1773, the Consumer Protection for Medical Debt Collections Act; HR 2813, Self-Insurance Protection Act; HR 2868, the Association Health Plans; HR 2880, the Protecting Patients Against PBM Abuses Act; HR 3799, CHOICE Arrangement Act; HR 3800, the Chronic Disease Flexible Coverage Act; HR 5609, the Advancing Health Savings Act; HR 5688, the Bipartisan HSA Improvement Act; HR 5687, the HSA Modernization Act; HR 6664, the Innovation in Pediatric Drugs Act; HR 6963, the Pediatric Cancer Drug Supply Chain Act; HR 7384, the Creating Hope Reauthorization Act; S 113, the Prescription Pricing for the People Act; S 127, the Pharmacy Benefit Manager Transparency Act; S 1339, the Pharmacy Benefit Manager Reform Act; S 1542, the DRUG Act; S 1967 the Patients Before Middlemen Act; S 2243, the Palliative Care and Hospice Education and Training Act; S 2483, the Strengthening Consumer Protections and Medical Debt Transparency Act; S 2973, the Modernizing and Ensuring PBM Accountability Act; S 3167, Multiple Employer Welfare Arrangement (MEWA) Act; Legislation to protect insurance purchasers interacting with insurance brokers; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; FDA draft guidance related to dose optimization studies in clinical trials

HR 3991 / S 1624, the Gabriella Miller Kids First Act; Implementation of the Childhood Cancer STAR Act (enacted in 2022);

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S. 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

FY24 & FY25 appropriations for the National Cancer Institute, specifically funding for programs related to the Childhood Cancer STAR Reauthorization Act and the Childhood Cancer Data Initiative (CCDI); FY24 & FY25 appropriations for the Department of Defense Congressionally-directed Medical Research Programs; FY24 & FY25 appropriations for the Food and Drug Administration